mSphere · 2019 · 19 citations · 51 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyConjugate VaccinesMucosal VaccinesVaccinationVaccine DeliveryVaccine Delivery SystemsVaccine PlatformsAdjuvant DeliveryConjugate Vaccine AdjuvantsHost-pathogen Interactions At Mucosal SurfacesLiposome AdjuvantsLiposome ImmunogenicityLiposomesMucosal Immunization Against Enteric PathogensVaccine Delivery Formulations
Campylobacter jejuni is a leading cause of diarrheal disease worldwide, and currently no preventative interventions are available. C. jejuni is an invasive mucosal pathogen that has a variety of polysaccharide structures on its surface, including a capsule. In phase 1 studies, a C. jejuni capsule conjugate vaccine was safe but poorly immunogenic when delivered alone or with aluminum hydroxide. Here, we report enhanced immunogenicity of the conjugate vaccine delivered with liposome adjuvants containing monophosphoryl lipid A without or with QS-21, known as ALF and ALFQ, respectively, in preclinical studies. Both liposome adjuvants significantly enhanced immunity in mice and nonhuman primates and improved protective efficacy of the vaccine compared to alum in a nonhuman primate C. jejuni diarrhea model, providing promising evidence that these potent adjuvant formulations may enhance immunogenicity in upcoming human studies with this C. jejuni conjugate and other malaria and HIV vaccine platforms.
51
Karen L. Kotloff, James P. Nataro, William C. Blackwelder et al. · The Lancet · 2013 · 3.6K citations
Roman Prymula, Pascal Peeters, Viktor Chrobok et al. · The Lancet · 2006 · 640 citations